Clinical Trial Update: CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a CRISPR-edited anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CRISPR-delivered anti-BCMA CAR-T

Snippet

Sponsor: Thomas Martin, MD | Conditions: Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Status: RECRUITING